AMLX - Amylyx Pharmaceuticals

-

$undefined

N/A

(N/A)

Amylyx Pharmaceuticals NasdaqGS:AMLX Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. Its lead products candidate includes avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Location: 43 Thorndike Street, Cambridge, MA, 02141, United States | Website: https://amylyx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

234.1M

Cash

204.1M

Avg Qtr Burn

-51.75M

Short % of Float

8.93%

Insider Ownership

12.47%

Institutional Own.

85.84%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Relyvrio (AMX0035) Details
Amyotrophic lateral sclerosis

Approved

Update

Avexitide Details
Post-Bariatric Hypoglycemia (PBH)

Phase 3

Data readout

AMX0035 Details
Progressive supranuclear palsy

Phase 3

Data readout

Relyvrio (AMX0035) Details
Amyotrophic lateral sclerosis

Phase 3

Update

AMX0035 Details
Alzheimer's disease

Phase 2

Update

AMX0035 Details
Wolfram syndrome

Phase 2

Update

AMX0114 Details
Amyotrophic lateral sclerosis

Phase 1

Data readout